by Manon FRACHON | 7 Jan Tue | English
Investment will support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy secondary to age-related macular degeneration (AMD); Aviceda’s ongoing Phase 2b/3 trial evaluating AVD-104 is fully enrolled, with 12-month...
by Manon FRACHON | 22 Nov Fri | English
Paris, France, November 22nd 2024 – Jeito is pleased to announce that Dr Rafaèle Tordjman has received L’Agefi’s prestigious 2024 ‘AM Leader’ Award at L’Agefi’s annual “Grands Prix” ceremony. The award recognizes...
by Manon FRACHON | 12 Nov Tue | English
Building on its co-lead investments in Alentis Therapeutics’ Series B (2021) and Series C (2023) rounds, Jeito’s renewed commitment demonstrates its strategy of supporting promising portfolio companies through key value-creation milestones. Financing will advance...
by Manon FRACHON | 16 Jul Tue | English
This new financing will support broad late-stage clinical development program for visugromab, CatalYm’s lead product candidate in cancer immunotherapy. After a first investment as co-lead investor in CatalYm’s €50 million series C financing (November 2022), Jeito’s...
by Manon FRACHON | 29 May Wed | English
This acquisition reflects the significant clinical progress achieved with Restoret™,EyeBio’s novel late-phase candidate for diabetic macular edema,as well as a preclinical pipeline targeting retinal diseases – Restoret anticipated to enter pivotal study for...
Recent Comments